TISIDB

Summary
Symbol	TAPBP
Name	TAP binding protein (tapasin)
Aliases	TAPA; NGS17; TPN; TPSN; NGS-17; TAP-associated protein; TAP-binding protein; Tapasin
Chromosomal Location	6p21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Endoplasmic reticulum membrane Single-pass type I membrane protein
Domain	PF07654 Immunoglobulin C1-set domain
Function	Involved in the association of MHC class I with transporter associated with antigen processing (TAP) and in the assembly of MHC class I with peptide (peptide loading).

> Gene Ontology [ TOP ]
Biological Process	GO:0002474 antigen processing and presentation of peptide antigen via MHC class I GO:0002483 antigen processing and presentation of endogenous peptide antigen GO:0006890 retrograde vesicle-mediated transport, Golgi to ER GO:0019882 antigen processing and presentation GO:0019883 antigen processing and presentation of endogenous antigen GO:0019885 antigen processing and presentation of endogenous peptide antigen via MHC class I GO:0048002 antigen processing and presentation of peptide antigen GO:0048193 Golgi vesicle transport GO:0050822 peptide stabilization GO:0050823 peptide antigen stabilization GO:0061635 regulation of protein complex stability
Molecular Function	GO:0003823 antigen binding GO:0015399 primary active transmembrane transporter activity GO:0015405 P-P-bond-hydrolysis-driven transmembrane transporter activity GO:0015433 peptide antigen-transporting ATPase activity GO:0015440 peptide-transporting ATPase activity GO:0016820 hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of substances GO:0016887 ATPase activity GO:0022804 active transmembrane transporter activity GO:0033218 amide binding GO:0042277 peptide binding GO:0042287 MHC protein binding GO:0042288 MHC class I protein binding GO:0042605 peptide antigen binding GO:0042623 ATPase activity, coupled GO:0042626 ATPase activity, coupled to transmembrane movement of substances GO:0043492 ATPase activity, coupled to movement of substances GO:0046977 TAP binding GO:0046978 TAP1 binding GO:0046979 TAP2 binding GO:0051082 unfolded protein binding
Cellular Component	GO:0030176 integral component of endoplasmic reticulum membrane GO:0031227 intrinsic component of endoplasmic reticulum membrane GO:0042824 MHC class I peptide loading complex GO:0042825 TAP complex GO:0071556 integral component of lumenal side of endoplasmic reticulum membrane GO:0098552 side of membrane GO:0098553 lumenal side of endoplasmic reticulum membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04612 Antigen processing and presentation
Reactome	R-HSA-1280218: Adaptive Immune System R-HSA-983170: Antigen Presentation R-HSA-1236975: Antigen processing-Cross presentation R-HSA-983169: Class I MHC mediated antigen processing & presentation R-HSA-1236974: ER-Phagosome pathway R-HSA-168256: Immune System

Summary
Symbol	TAPBP
Name	TAP binding protein (tapasin)
Aliases	TAPA; NGS17; TPN; TPSN; NGS-17; TAP-associated protein; TAP-binding protein; Tapasin
Chromosomal Location	6p21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between TAPBP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between TAPBP and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
26381407	Melanoma	Promote immunity	This treatment combined with tapasin reconstitution and IFN-γ stimulation restored the highest level of HLA class I expression and its ability to elicit cytotoxic T cell responses.
16517708	Head and Neck Squamous Cell Carcinoma	Promote immunity (T cell function)	First, lack of recognition of SCCHN cells by CTL is associated with marked down-regulation of the IFN-gamma-inducible APM components low-m.w. protein 2, TAP1, TAP2, and tapasin.
28783722	Melanoma	Promote immunity (T cell function); essential for immunotherapy	On the basis of our initial optimization of the 2CT-CRISPR assay, we expected that genes directly associated with MHC class I antigen processing and presentation would be enriched in our screens, and found that HLA-A, B2M, TAP1, TAP2, and TAPBP were among the most highly-enriched genes in our screen
28783722	Melanoma	Promote immunity (T cell function)	Fifteen genes showed significant resistance to T-cell-mediated cytolysis with at least 1 sgRNA in these cells.

Summary
Symbol	TAPBP
Name	TAP binding protein (tapasin)
Aliases	TAPA; NGS17; TPN; TPSN; NGS-17; TAP-associated protein; TAP-binding protein; Tapasin
Chromosomal Location	6p21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of TAPBP in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 1.33	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	STARS Score: 5.36; FDR: 0.001	Resistant to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX	STARS Score: 4.07; FDR: 0.021	Resistant to T cell-mediated killing
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	TAPBP
Name	TAP binding protein (tapasin)
Aliases	TAPA; NGS17; TPN; TPSN; NGS-17; TAP-associated protein; TAP-binding protein; Tapasin
Chromosomal Location	6p21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of TAPBP in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.261	0.268
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.159	0.822
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.338	0.515
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.66	0.103
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.84	0.757
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.432	0.901
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.321	0.515
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.546	0.773
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.001	1
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.789	0.732
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.75	0.826
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.014	0.846

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of TAPBP in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	5.9	-5.9	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	4.1	7	0.339
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	5.1	6	0.373
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	TAPBP
Name	TAP binding protein (tapasin)
Aliases	TAPA; NGS17; TPN; TPSN; NGS-17; TAP-associated protein; TAP-binding protein; Tapasin
Chromosomal Location	6p21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TAPBP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	TAPBP
Name	TAP binding protein (tapasin)
Aliases	TAPA; NGS17; TPN; TPSN; NGS-17; TAP-associated protein; TAP-binding protein; Tapasin
Chromosomal Location	6p21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TAPBP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TAPBP. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	TAPBP
Name	TAP binding protein (tapasin)
Aliases	TAPA; NGS17; TPN; TPSN; NGS-17; TAP-associated protein; TAP-binding protein; Tapasin
Chromosomal Location	6p21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TAPBP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	TAPBP
Name	TAP binding protein (tapasin)
Aliases	TAPA; NGS17; TPN; TPSN; NGS-17; TAP-associated protein; TAP-binding protein; Tapasin
Chromosomal Location	6p21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of TAPBP expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	TAPBP
Name	TAP binding protein (tapasin)
Aliases	TAPA; NGS17; TPN; TPSN; NGS-17; TAP-associated protein; TAP-binding protein; Tapasin
Chromosomal Location	6p21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between TAPBP and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	TAPBP
Name	TAP binding protein (tapasin)
Aliases	TAPA; NGS17; TPN; TPSN; NGS-17; TAP-associated protein; TAP-binding protein; Tapasin
Chromosomal Location	6p21.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting TAPBP collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse TAPBP